USP9X inhibitors

A compound represented by Formula (I):

• or a pharmaceutically acceptable salt thereof,
• wherein R1 and R10 are each independently selected from H, 2H, and substituted or unsubstituted alkyl;
• R2, R3, R4, R6, and R7 are each independently selected from H, 2H, halogen, substituted or unsubstituted alkyl, and substituted or unsubstituted alkoxy;
• R5 and R9 are each independently selected from H, 2H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, and halogen;
• R8 is substituted or unsubstituted 1- to 4-carbon alkylene;
• R11 is a hydrophobic alkyl selected from substituted or unsubstituted alkyl and substituted or unsubstituted cycloalkyl;
• Z1, Z2, and Z3 are each independently selected from CH and N;
• X1 is selected from —O—, —S—, —NH—, —CH2—;
• X2 is selected from -L-NRA—, -L-NRAC(O)—, -L-C(O)—, -L-OC(O)—, -L-C(O)O—, -L-CH(COORA)—, -L-C(O)NRA-L-, and -L-C(O)NRAC(O)—, wherein RA is selected from H, 2H, and substituted or unsubstituted alkyl;
• L is a linker group —(CH2)nCRBCRC(CH2)n—, wherein RB and RC are each independently selected from H, 2H, and substituted or unsubstituted alkyl;
• and wherein each n is independently 0, 1, or 2;
• and
• m is 1, 2, 3, or 4.